Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Alnylam Pharmaceuticals Inc | 1,334 |
| 2 | Human Genome Sciences Inc | 966 |
| 3 | Ionis Pharmaceuticals Inc | 838 |
| 4 | Fujifilm Corp | 831 |
| 5 | GlaxoSmithKline Biologicals SA | 791 |
| 6 | University of California San Diego UCSD | 767 |
| 7 | Novartis AG | 647 |
| 8 | Takeda Pharmaceutical Co Ltd | 578 |
| 9 | Novo Nordisk AS | 466 |
| 10 | Procter and Gamble Co | 459 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 54,955 |
| 2 | A61P | Therapeutic activity (drug indications) | 49,129 |
| 3 | C07K | Peptides | 24,677 |
| 4 | C12N | Microorganisms, enzymes | 23,899 |
| 5 | G01N | Investigating / analysing materials | 14,053 |
| 6 | C07D | Heterocyclic compounds | 8,654 |
| 7 | C12Q | Measuring/testing involving enzymes | 8,485 |
| 8 | Y02A | Climate change adaptation | 6,041 |
| 9 | Y10S | Cross-reference (legacy) | 3,988 |
| 10 | C12Y | Enzyme nomenclature (EC numbers) | 3,707 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| A kind of Septochol base-oxidation Curdlan polysaccharide nanoparticle and preparation method | 2016 | JIANGSU UNIVERSITY | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Drug Transport and Resistance Mechanisms | 29 |
| 2 | HIV Research and Treatment | 5 |
| 3 | Antifungal resistance and susceptibility | 4 |
| 4 | Bacteriophages and microbial interactions | 4 |
| 5 | Gallbladder and Bile Duct Disorders | 4 |
| 6 | Lipid Membrane Structure and Behavior | 4 |
| 7 | Monoclonal and Polyclonal Antibodies Research | 4 |
| 8 | Prion Diseases and Protein Misfolding | 4 |
| 9 | Enzyme Catalysis and Immobilization | 3 |
| 10 | Gastrointestinal motility and disorders | 3 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Youngro Byun | Seoul National University | 34 |
| 2 | Alan F. Hofmann | University of California San Diego | 31 |
| 3 | Junichi Goto | Tohoku University | 15 |
| 4 | Harris Bernstein | University of Arizona | 14 |
| 5 | A. Stiehl | Heidelberg University | 12 |
| 6 | Carol Bernstein | University of Arizona | 12 |
| 7 | Claire M. Payne | University of Arizona | 10 |
| 8 | Aldo Roda | University of Bologna | 10 |
| 9 | R. H. Dowling | Guy's Hospital | 10 |
| 10 | Hyun Tae Moon | GS Caltex (South Korea) | 9 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Assay of proteins in the presence of interfering materials | 1976 | 3205 | Mass Spectrometry Techniques and Applications |
| Solubilization of membranes by detergents | 1975 | 2935 | Lipid Membrane Structure and Behavior |
| Identification of a Nuclear Receptor for Bile Acids | 1999 | 2674 | Drug Transport and Resistance Mechanisms |
| Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome | 2013 | 2185 | Gut microbiota and health |
| lincRNAs act in the circuitry controlling pluripotency and differentiation | 2011 | 1897 | MicroRNA in disease regulation |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Degalol?
What are common synonyms for Degalol?
Which research topics are most associated with Degalol in the literature?
What are the leading research institutions and organizations studying Degalol?
How is Degalol patent activity distributed across technology classifications?